

**IN THE UNITED STATES DISTRICT COURT  
FOR THE NORTHERN DISTRICT OF OHIO  
EASTERN DIVISION**

IN RE NATIONAL PRESCRIPTION  
OPIATE LITIGATION

This document relates to:

*The State of Alabama v. Purdue Pharma L.P.,*  
No. 1:18-op-45236-DAP

MDL No. 2804

Case No. 17-md-2804

Hon. Dan Aaron Polster

**REQUEST FOR JUDICIAL NOTICE IN SUPPORT OF THE MANUFACTURER  
DEFENDANTS' JOINT MOTION TO DISMISS THE STATE OF ALABAMA'S FIRST  
AMENDED COMPLAINT**

PLEASE TAKE NOTICE that, pursuant to Federal Rule of Evidence 201, the Manufacturer Defendants hereby request that the Court take judicial notice of the following documents in support of the Manufacturer Defendants' Joint Motion to Dismiss The State of Alabama's First Amended Complaint. All exhibit references correspond to the exhibits attached to the Declaration of Sean O. Morris, filed contemporaneously in support of the above-referenced motion.

1. Exhibit A: The prescription drug label for OXYCONTIN® approved by the FDA as revised December 2016;
2. Exhibit B: The prescription drug label for OPANA® ER approved by the FDA a revised December 2016;

3. Exhibit C: DOJ press release entitled “Manhattan U.S. Attorney Announces \$39 Million Civil Fraud Settlement Against Qualitest Pharmaceuticals For Selling Half-Strength Fluoride Supplements” (Dec. 16, 2015);

4. Exhibit D: DOJ press release entitled “Mallinckrodt Agrees to Pay Record \$35 Million Settlement for Failure to Report Suspicious Orders of Pharmaceutical Drugs and for Recordkeeping Violations” (July 11, 2017); and

5. Exhibit E: Alabama Drug Abuse Task Force’s Report to the Alabama Legislature (February 15, 2013).

All of these exhibits are properly subject to judicial notice. Courts routinely take judicial notice of FDA-approved labels (Exhibit A & B) and governmental press releases (Exhibits C, D & E). *See, e.g., Aaron v. Medtronic, Inc.*, 209 F. Supp. 3d 994, 1014 (S.D. Ohio 2016) (citing *Chapman v. Abbott Labs.*, 930 F. Supp. 2d 1321, 1323 (M.D. Fla. 2013) (FDA drug label)); *Reeves v. PharmaJet Inc.*, 846 F. Supp.2d 791, 794 n.1 (N.D. Ohio 2012) (“The Court may also take judicial notice of matters of public record including records of the FDA available on its website.”); *Kiker v. SmithKline Beecham Corp.*, 2016 WL 8189286, at \*4 n.3 (S.D. Ohio Dec. 15, 2016) (press releases); *see also Beaver Cty. Ret. Bd. v. LCA-Vision Inc.*, 2009 WL 806714, at \*7 (S.D. Ohio Mar. 25, 2009) (finding that accuracy of press releases cannot be reasonably questioned, and noting that “[p]ress releases also are self-authenticating under evidentiary rule 902(6)”).

**WHEREFORE**, the Manufacturer Defendants respectfully request that the Court take judicial notice of the abovementioned exhibits.

Dated: June 29, 2018

Respectfully submitted,

/s/ Mark S. Cheffo

---

Mark S. Cheffo  
Sheila L. Birnbaum  
Hayden A. Coleman  
DECHERT LLP  
Three Bryant Park  
1095 Avenue of the Americas  
New York, NY 10036  
Tel: (212) 698-3500  
Mark.Cheffo@dechert.com  
Sheila.Birnbaum@dechert.com  
Hayden.Coleman@dechert.com

*Attorneys for Defendants Purdue Pharma L.P., Purdue Pharma Inc., and The Purdue Frederick Company*

/s/ Jonathan L. Stern (consent)

Jonathan L. Stern  
Arnold & Porter Kaye Scholer LLP  
601 Massachusetts Ave. NW  
Washington, DC 20001  
Tel: (202) 942-5000  
jonathan.stern@arnoldporter.com

Sean O. Morris  
Arnold & Porter Kaye Scholer LLP  
777 S. Figueroa St., Suite 4400  
Los Angeles, CA 90017  
Tel: (213) 243-4000  
sean.morris@arnoldporter.com

*Attorneys for Defendants Endo Health Solutions Inc. and Endo Pharmaceuticals Inc.*

/s/ Steven F. Napolitano (consent)

Steven F. Napolitano  
Skarzynski Black  
One Battery Park Plaza 32<sup>nd</sup> Floor  
New York, New York 10004  
Tel: (212) 820-7746

snapolitano@skarzynski.com

*Attorneys for Defendant Rhodes  
Pharmaceuticals L.P.*